Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Notes Payables (2016 - 2019)

Historic Notes Payables for Lineage Cell Therapeutics (LCTX) over the last 5 years, with Q1 2019 value amounting to $18000.0.

  • Lineage Cell Therapeutics' Notes Payables fell 8500.0% to $18000.0 in Q1 2019 from the same period last year, while for Mar 2019 it was $18000.0, marking a year-over-year decrease of 8500.0%. This contributed to the annual value of $70000.0 for FY2018, which is 5394.74% down from last year.
  • According to the latest figures from Q1 2019, Lineage Cell Therapeutics' Notes Payables is $18000.0, which was down 8500.0% from $70000.0 recorded in Q4 2018.
  • Over the past 5 years, Lineage Cell Therapeutics' Notes Payables peaked at $2.6 million during Q2 2017, and registered a low of $18000.0 during Q1 2019.
  • Moreover, its 5-year median value for Notes Payables was $123000.0 (2017), whereas its average is $391812.5.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Notes Payables soared by 258947.37% in 2017 and then crashed by 9530.33% in 2018.
  • Lineage Cell Therapeutics' Notes Payables (Quarter) stood at $95000.0 in 2015, then skyrocketed by 776.84% to $833000.0 in 2016, then tumbled by 81.75% to $152000.0 in 2017, then tumbled by 53.95% to $70000.0 in 2018, then tumbled by 74.29% to $18000.0 in 2019.
  • Its last three reported values are $18000.0 in Q1 2019, $70000.0 for Q4 2018, and $70000.0 during Q3 2018.